Zhongheng Group: Holding subsidiary Lai Mei Pharmaceutical Company receives drug registration certificate.

The announcement of Zhongheng Group stated that its holding subsidiary, Lai Mei Pharmaceuticals, recently received the "Drug Registration Certificate" for two drugs, nicorandil tablets and ketorolac tromethamine injection. Nicorandil tablets are used for the treatment of angina, while ketorolac tromethamine injection is used for the short-term treatment of moderate to severe acute postoperative pain. Lai Mei Pharmaceuticals has invested a total of RMB 5.3879 million and RMB 4.7431 million in the research and development of these two drugs, respectively. Obtaining the registration certificate will help to further enrich the company's product line.